Loading company…
Cambridge-based company developing live biotherapeutics for bacterial infections, antimicrobial resistance and GI immune diseases.
Founded in 2010 and headquartered in Massachusetts, US, Seres Therapeutics, Inc. develops live biotherapeutics using a microbiome restoration platform, aimed at preventing bacterial bloodstream infections and treating gastrointestinal immune diseases. Revenue comes from partnerships, milestone payments and royalties. In October 2025 it received USD 3.6 million in grant funding from CARB-X to develop a liquid formulation of SER-155. It is listed at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in